TP53 and gastric adenocarcinoma: We identified the cell cycle as being the most frequent subject of mutations, followed by alterations to the RTK/RAS, TP53, and PI3K/PTEN pathways, where simultaneous mutations within the latter three proteins occurs in 15.1% of patients with STAD (Figure S1B).